Lethal and rescuer genes are defined as genes that when inactivated result in cell death or enhanced cell growth, respectively. The ability to identify these genes in large-scale automated screening ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "RNA Interference Therapy-Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The "RNA Interference Therapy - Competitive ...

SAN FRANCISCO (AP) _ The biotechnology field is littered with the debris of would-be miracle cures. These days, the buzz is building around a technology called ``RNA interference,'' whose legions of ...

Business Strategy and Outlook Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

(MENAFN- GlobeNewsWire - Nasdaq) RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing ...